Skip to main content

Advertisement

SpringerLink
Log in

Shooting Cancer With Magic Bullets

Promises and Challenges of Antibody-drug Conjugates

  • General Article
  • Published:
Resonance Aims and scope Submit manuscript

Abstract

Antibody-drug conjugates (ADCs) are strategically designed formulations for the targeted elimination of cancer cells without causing severe side effects. ADCs first recognise and bind to specific receptors on cancer cells and then enter the cells via endocytosis. Inside the cells, the cytotoxic agent attached to the ADC is released and kills the cells by disrupting the latter’s defined target. Despite their superior efficacy over classic chemotherapeutics, ADCs face drug resistance in some patients. Novel ADCs are in development to address these challenges.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Suggested Reading

  1. J. G. Nirmala and M. Lopus, Cell death mechanisms in eukaryotes, Cell Biol. Toxicol., 36, pp.145–164, 2020.

    Article  Google Scholar 

  2. M. Lopus, Antibody-DM1 conjugates as cancer therapeutics, Cancer Lett., 307, pp.113–118, 2011.

    Article  Google Scholar 

  3. M. Lopus, E. Oroudjev, L. Wilson, S. Wilhelm, W. Widdison, R. Chari, M.A. Jordan, Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules, Mol Cancer Ther., 9, pp.2689–2699

  4. E. Oroudjev, M. Lopus, L. Wilson, C. Audette, C. Provenzano, H. Erickson, Y. Kovtun, R. Chari, M.A. Jordan, Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability, Mol. Cancer Ther., 9, pp.2700–2713, 2010.

    Article  Google Scholar 

  5. P. Zhao, Y. Zhang, W. Li, C. Jeanti, G. Xiang, Y. Dong, Recent advances of antibody-drug conjugates for clinical applications, Acta Pharmaceutica Sinica B, 10, pp.1589–1600, 2020.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Biological Sciences UM-DAE Centre for Excellence In Basic Sciences, University of Mumbai Kalina Campus, Mumbai, 400 098, India

    Manu Lopus

Authors
  1. Manu Lopus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manu Lopus.

Additional information

Manu Lopus is a Reader at the School of Biological Sciences and Principal Investigator, Experimental Cancer Therapeutics and Chemical Biology Laboratory, UM-DAE Centre for Excellence in Basic Sciences, Mumbai. He works on non-apoptotic cell death mechanisms, green-nanotechnology-assisted drug design strategies, and the regulation of microtubule dynamics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lopus, M. Shooting Cancer With Magic Bullets. Reson 27, 1127–1130 (2022). https://doi.org/10.1007/s12045-022-1409-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12045-022-1409-z

Keywords

Search

Navigation